Observational Study in Multiple System Atrophy

Key facts

Sponsor

H. Lundbeck A/S

Principal Investigator

Email contact via H. Lundbeck A/S

LundbeckClinicalTrials@Lundbeck.com

Intervention

plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort(diagnostic_test)

Enrollment

90 enrolled

Eligibility

40-75 years · All sexes

Timeline

2022 – 2031

Study locations (8)

• Beijing Tiantan Hospital, Capital Medical University, Beijing, China
• Beijing Xuanwu Hospital, Capital Medical University, Beijing, China
• Beijing Hospital, Beijing, China
• Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
• Xiangya Hospital of Central South University, Changsha, China
• West China Hospital of Sichuan University, Chengdu, China
• Huashan Hospital of Fudan University, Shanghai, China
• The Second Affiliated Hospital of Soochow University, Suzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare parkinsonian syndrome due to neurodegenerative disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06785948
  tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden
  Association de Recherche Bibliographique pour les Neurosciences
• RECRUITINGNANCT06072105
  Medical Decision Making in Multiple System Atrophy
  Medical University Innsbruck
• RECRUITINGNANCT04250493
  Insulin Resistance in Multiple System Atrophy
  University Hospital, Bordeaux
• RECRUITINGNCT02194816
  Modifiable Variables in Parkinsonism (MVP)
  Bastyr University

See all trials for Rare parkinsonian syndrome due to neurodegenerative disease →